Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue, Rash, Sinusitis
Clinical narrative: Patient took the first dose on 9-feb/ The patient asked if it is ok for her to get the second dose of the Moderna COVID-19 vaccine; rash all over body, lips, and tongue, legs and body which looked like measles/allergic reaction; Patient providing update: 9 days after the Moderna COVID-19 vaccine, developed a sinus infection for which she received antibiotics, may be responsible for allergic reaction; This spontaneous case was reported by a consumer and describes the occurrence of SINUSITIS (Patient providing update: 9 days after the Moderna COVID-19 vaccine, developed a sinus infection for which she received antibiotics, may be responsible for allergic reaction), PRODUCT DOSE OMISSION ISSUE (Patient took the first dose on 9-feb/ The patient asked if it is ok for her to get the second dose of the Moderna COVID-19 vaccine) and RASH (rash all over body, lips, and tongue, legs and body which looked like measles/allergic reaction) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Feb-2021, the patient experienced SINUSITIS (Patient providing update: 9 days after the Moderna COVID-19 vaccine, developed a sinus infection for which she received antibiotics, may be responsible for allergic reaction). On 28-Feb-2021, the patient experienced RASH (rash all over body, lips, and tongue, legs and body which looked like measles/allergic reaction). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Patient took the first dose on 9-feb/ The patient asked if it is ok for her to get the second dose of the Moderna COVID-19 vaccine). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) in 2021 for Rash all over, at a dose of UNK dosage form. At the time of the report, SINUSITIS (Patient providing update: 9 days after the Moderna COVID-19 vaccine, developed a sinus infection for which she received antibiotics, may be responsible for allergic reaction) and RASH (rash all over body, lips, and tongue, legs and body which looked like measles/allergic reaction) outcome was unknown and PRODUCT DOSE OMISSION ISSUE (Patient took the first dose on 9-feb/ The patient asked if it is ok for her to get the second dose of the Moderna COVID-19 vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered RASH (rash all over body, lips, and tongue, legs and body which looked like measles/allergic reaction) to be not related. No further causality assessments were provided for SINUSITIS (Patient providing update: 9 days after the Moderna COVID-19 vaccine, developed a sinus infection for which she received antibiotics, may be responsible for allergic reaction) and PRODUCT DOSE OMISSION ISSUE (Patient took the first dose on 9-feb/ The patient asked if it is ok for her to get the second dose of the Moderna COVID-19 vaccine).    No concomitant medications were reported.  The patient called in to provide an update on her adverse event as well as present a medical information question. The patient had originally called in on 03-MAR-2021 to report an allergic reaction that she developed after receiving the Moderna COVID-19 vaccine. The patient received the first dose of the Moderna COVID-19 vaccine on 09-FEB-2021, and reported that 9 days after the vaccine she was diagnosed with a sinus infection and received antibiotics. The patient reported that there might be a chance that the allergic reaction originally reported could be from the antibiotics that she received. The patient asked if it was ok for her to get the second dose of the Moderna COVID-19 vaccine, given her history of allergic reactions.   Most recent FOLLOW-UP information incorporated above includes: On 30-Jul-2021: Follow-up received: Additional events (sinusitis infection and missed dose), causality of the reporter for the event rash and Sender's (Case) Safety Report Unique Identifier was updated.